Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to 21.48%.

  • Capricor Therapeutics' EBITDA Margin fell 158400.0% to 21.48% in Q4 2024 from the same period last year, while for Sep 2025 it was 243.47%, marking a year-over-year decrease of 1226400.0%. This contributed to the annual value of 99.25% for FY2024, which is 110800.0% down from last year.
  • Latest data reveals that Capricor Therapeutics reported EBITDA Margin of 21.48% as of Q4 2024, which was down 158400.0% from 557.8% recorded in Q3 2024.
  • Capricor Therapeutics' EBITDA Margin's 5-year high stood at 5.65% during Q4 2023, with a 5-year trough of 23187.59% in Q3 2020.
  • For the 5-year period, Capricor Therapeutics' EBITDA Margin averaged around 3523.95%, with its median value being 476.82% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -220567500bps in 2020, then skyrocketed by 46924500bps in 2021.
  • Quarter analysis of 5 years shows Capricor Therapeutics' EBITDA Margin stood at 7262.67% in 2020, then soared by 68bps to 2326.65% in 2021, then soared by 65bps to 803.65% in 2022, then skyrocketed by 99bps to 5.65% in 2023, then crashed by -280bps to 21.48% in 2024.
  • Its EBITDA Margin was 21.48% in Q4 2024, compared to 557.8% in Q3 2024 and 282.01% in Q2 2024.